A government investigation revealed that EVT, a Guidant subsidiary, failed to file 2,628 adverse event reports relating to its Ancure endograft system, which is a surgically implantable device used to treat abdominal aortic aneurysms. Out of the adverse events that were not reported, 12 involved patient deaths and 57 involved emergency procedures where a physician converted an operation into a more invasive procedure. As a result of its failures, EVT pleaded guilty to 10 felonies, including nine counts of introducing misbranded devices into interstate commerce and one count of making false statements to the FDA. The company paid $92.4 million in criminal and civil fines.